Our top pick for
Fortress Biotech Inc is a biotechnology business based in the US. Fortress Biotech shares (FBIO) are listed on the NASDAQ and all prices are listed in US Dollars. Fortress Biotech employs 111 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$3.08|
|52-week range||$2.12 - $6.10|
|50-day moving average||$3.26|
|200-day moving average||$3.61|
|Wall St. target price||$10.17|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.42|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-08)||3.01%|
|1 month (2021-09-17)||-8.06%|
|3 months (2021-07-16)||3.08|
|6 months (2021-04-16)||-25.24%|
|1 year (2020-10-16)||11.59%|
|2 years (2019-10-16)||136.92%|
|3 years (2018-10-16)||138.76%|
|5 years (2016-10-14)||17.11%|
|Revenue TTM||$52.7 million|
|Gross profit TTM||$31 million|
|Return on assets TTM||-21.66%|
|Return on equity TTM||-55.27%|
|Market capitalisation||$302.2 million|
TTM: trailing 12 months
There are currently 927,253 Fortress Biotech shares held short by investors – that's known as Fortress Biotech's "short interest". This figure is 17.3% up from 790,697 last month.
There are a few different ways that this level of interest in shorting Fortress Biotech shares can be evaluated.
Fortress Biotech's "short interest ratio" (SIR) is the quantity of Fortress Biotech shares currently shorted divided by the average quantity of Fortress Biotech shares traded daily (recently around 311158.72483221). Fortress Biotech's SIR currently stands at 2.98. In other words for every 100,000 Fortress Biotech shares traded daily on the market, roughly 2980 shares are currently held short.
However Fortress Biotech's short interest can also be evaluated against the total number of Fortress Biotech shares, or, against the total number of tradable Fortress Biotech shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Fortress Biotech's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Fortress Biotech shares in existence, roughly 10 shares are currently held short) or 0.0147% of the tradable shares (for every 100,000 tradable Fortress Biotech shares, roughly 15 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Fortress Biotech.
Find out more about how you can short Fortress Biotech stock.
We're not expecting Fortress Biotech to pay a dividend over the next 12 months.
Over the last 12 months, Fortress Biotech's shares have ranged in value from as little as $2.12 up to $6.1. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Fortress Biotech's is 2.3974. This would suggest that Fortress Biotech's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Fortress Biotech, Inc. , a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Ximino capsules to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris; Targadox for severe acne; Exelderm cream for ringworm and jock itch symptoms; Ceracade for dry skin conditions; Luxamend for dressing and managing wounds; and Accutane capsules for severe recalcitrant nodular acne. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; MB-107 and MB-207 for the treatment of X-linked severe combined immunodeficiency; Cosibelimab for metastatic cancers; CK-101 for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and CEVA101 for the treatment of severe traumatic brain injury in adults and children. The company's early stage product candidates include MB-102 for blastic plasmacytoid dendritic cell neoplasm; MB-101 for glioblastoma; MB-104 for multiple myeloma and light chain amyloidosis; MB-106 for B-cell non-hodgkin lymphoma; MB-103 for GBM & metastatic breast cancer to brain; MB-108; MB-105 for prostate and pancreatic cancers; and BAER-101. Its preclinical product candidates comprise AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; ConVax; and ONCOlogues, and oligonucleotide platform. It has collaboration arrangements with universities, research institutes, and pharmaceutical companies.
Everything we know about the Aura Biosciences IPO, plus information on how to buy in.
Everything we know about the Claros Mortgage Trust IPO, plus information on how to buy in.
Everything we know about the Evotec SE IPO, plus information on how to buy in.
Everything we know about the Delimobil Holding SA IPO, plus information on how to buy in.
Everything we know about the Blue Water Vaccines IPO, plus information on how to buy in.
Everything we know about the Sonendo IPO, plus information on how to buy in.
Everything we know about the FlexEnergy Green Solutions IPO, plus information on how to buy in.
Everything we know about the Stran & Company IPO, plus information on how to buy in.
Everything we know about the Kidpik Corp IPO, plus information on how to buy in.
Everything we know about the Nuvectis Pharma IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.